BR0209990A - Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células - Google Patents
Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de célulasInfo
- Publication number
- BR0209990A BR0209990A BR0209990-0A BR0209990A BR0209990A BR 0209990 A BR0209990 A BR 0209990A BR 0209990 A BR0209990 A BR 0209990A BR 0209990 A BR0209990 A BR 0209990A
- Authority
- BR
- Brazil
- Prior art keywords
- destruction
- conditions requiring
- treating tumors
- cell removal
- requiring cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Abstract
"PEPTìDEOS EFETIVOS NO TRATAMENTO DE TUMORES E OUTRAS CONDIçõES QUE REQUEREM A REMOçãO OU DESTRUIçãO DE CéLULAS". A presente invenção e dirigida a métodos de tratamento de condições que requerem remoção ou destruição de células danosas ou indesejadas em um paciente, tal como tumores benígnos e malígnos, usando peptídeos derivados das seq³ências de amino ácidos de proteínas em cadeia neurais, e moléculas relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29315601P | 2001-05-25 | 2001-05-25 | |
PCT/CA2002/000759 WO2002097030A2 (en) | 2001-05-25 | 2002-05-24 | Peptides derived from neural thread proteins and their medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209990A true BR0209990A (pt) | 2004-06-29 |
Family
ID=23127882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209990-0A BR0209990A (pt) | 2001-05-25 | 2002-05-24 | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células |
Country Status (17)
Country | Link |
---|---|
US (1) | US6924266B2 (pt) |
EP (1) | EP1390403B1 (pt) |
JP (1) | JP4584573B2 (pt) |
KR (1) | KR100945383B1 (pt) |
CN (1) | CN1582301A (pt) |
AT (1) | ATE350396T1 (pt) |
AU (1) | AU2002256587B2 (pt) |
BR (1) | BR0209990A (pt) |
CA (1) | CA2448348C (pt) |
CY (1) | CY1111120T1 (pt) |
DE (1) | DE60217326T2 (pt) |
DK (1) | DK1390403T3 (pt) |
ES (1) | ES2278916T3 (pt) |
NO (1) | NO334189B1 (pt) |
NZ (1) | NZ529911A (pt) |
PT (1) | PT1390403E (pt) |
WO (1) | WO2002097030A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074323A2 (en) * | 2001-03-08 | 2002-09-26 | Nymox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
EP1847550A3 (en) * | 2001-07-19 | 2008-01-09 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
CN100475843C (zh) * | 2001-07-19 | 2009-04-08 | 尼莫克斯股份有限公司 | 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽 |
US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
WO2005075647A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
EP1732594A4 (en) * | 2004-03-18 | 2007-10-17 | St Lukes Hospital | METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE |
BRPI0708737A2 (pt) * | 2006-03-10 | 2011-06-14 | Nymox Corp | mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural |
CN101215323B (zh) * | 2007-12-28 | 2011-11-30 | 首都医科大学宣武医院 | 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 |
US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
CN111579799A (zh) * | 2020-06-23 | 2020-08-25 | 江苏省荣军医院 | 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
DE68927459T2 (de) | 1988-12-21 | 1997-04-24 | Gen Hospital Corp | Nachweis einer neurologischen Krankheit oder einer Funktionsstörung |
KR20000075748A (ko) * | 1997-02-26 | 2000-12-26 | 마빈 씨. 구트리 | 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계 |
WO1999019347A1 (en) | 1997-10-10 | 1999-04-22 | Astrazeneca Ab | Synthetic genes with immunomodulatory effects |
CA2335986A1 (en) * | 1998-06-26 | 2000-01-06 | Simeng Suy | Use of tempo and tempo derivatives for inducing cell death |
US7125957B1 (en) * | 1998-09-30 | 2006-10-24 | Riken | VPR mutant protein and its encoding gene having apoptosis-inducing action |
WO2000034477A2 (en) * | 1998-12-11 | 2000-06-15 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
DK1143994T3 (da) * | 1999-01-11 | 2003-10-20 | Leadd Bv | Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme |
WO2000063230A2 (en) | 1999-03-26 | 2000-10-26 | Human Genome Sciences, Inc. | 49 human secreted proteins |
EP1165827A4 (en) | 1999-03-26 | 2003-05-02 | Human Genome Sciences Inc | 45 HUMAN SECRETED PROTEINS |
US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
WO2002074323A2 (en) | 2001-03-08 | 2002-09-26 | Nymox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
CA2446945A1 (en) | 2001-05-16 | 2002-11-21 | Nymox Corporation | Method of preventing cell death using segments of neural thread proteins |
-
2002
- 2002-05-24 PT PT02726037T patent/PT1390403E/pt unknown
- 2002-05-24 NZ NZ529911A patent/NZ529911A/en not_active IP Right Cessation
- 2002-05-24 DK DK02726037T patent/DK1390403T3/da active
- 2002-05-24 WO PCT/CA2002/000759 patent/WO2002097030A2/en active IP Right Grant
- 2002-05-24 AU AU2002256587A patent/AU2002256587B2/en not_active Ceased
- 2002-05-24 ES ES02726037T patent/ES2278916T3/es not_active Expired - Lifetime
- 2002-05-24 US US10/153,334 patent/US6924266B2/en not_active Expired - Fee Related
- 2002-05-24 AT AT02726037T patent/ATE350396T1/de active
- 2002-05-24 CN CNA028149777A patent/CN1582301A/zh active Pending
- 2002-05-24 KR KR1020037015376A patent/KR100945383B1/ko not_active IP Right Cessation
- 2002-05-24 CA CA2448348A patent/CA2448348C/en not_active Expired - Fee Related
- 2002-05-24 BR BR0209990-0A patent/BR0209990A/pt not_active IP Right Cessation
- 2002-05-24 EP EP02726037A patent/EP1390403B1/en not_active Expired - Lifetime
- 2002-05-24 JP JP2003500199A patent/JP4584573B2/ja not_active Expired - Fee Related
- 2002-05-24 DE DE60217326T patent/DE60217326T2/de not_active Expired - Lifetime
-
2003
- 2003-11-25 NO NO20035231A patent/NO334189B1/no not_active IP Right Cessation
-
2007
- 2007-03-12 CY CY20071100339T patent/CY1111120T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR100945383B1 (ko) | 2010-03-05 |
CN1582301A (zh) | 2005-02-16 |
ATE350396T1 (de) | 2007-01-15 |
NO20035231D0 (no) | 2003-11-25 |
WO2002097030A3 (en) | 2003-10-30 |
NO20035231L (no) | 2004-01-26 |
AU2002256587B2 (en) | 2008-04-03 |
JP2004534533A (ja) | 2004-11-18 |
JP4584573B2 (ja) | 2010-11-24 |
CY1111120T1 (el) | 2015-06-11 |
ES2278916T3 (es) | 2007-08-16 |
EP1390403B1 (en) | 2007-01-03 |
US6924266B2 (en) | 2005-08-02 |
KR20040038913A (ko) | 2004-05-08 |
NZ529911A (en) | 2008-05-30 |
CA2448348C (en) | 2013-07-16 |
EP1390403A2 (en) | 2004-02-25 |
DE60217326D1 (de) | 2007-02-15 |
WO2002097030A2 (en) | 2002-12-05 |
CA2448348A1 (en) | 2002-12-05 |
DE60217326T2 (de) | 2007-10-18 |
PT1390403E (pt) | 2007-03-30 |
NO334189B1 (no) | 2014-01-13 |
US20030096350A1 (en) | 2003-05-22 |
DK1390403T3 (da) | 2007-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213786A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
BR0211199A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
BR0209990A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
CY1109650T1 (el) | Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων | |
NO20013493D0 (no) | Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser | |
ATE536366T1 (de) | Peptidinhibitoren von hk2 und deren anwendung | |
ATE479705T1 (de) | Reduzierter slam abhängiger zell eintritt | |
EP1714979A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
EP1847550A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
NO20040221L (no) | Peptider til fjerning eller destruksjon av celler | |
AU3811395A (en) | Identification of the p21waf1-pcna interaction site and therapeutic applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |